^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    elafibranor (GFT505)

    i
    Other names: GFT505, GFT 505, GFT-505, IPN60190
    Associations

    News

    Trials
    Company:
    Genfit, Ipsen
    Drug class:
    PPAR α agonist, PPAR δ agonist
    Related drugs:
    Associations

    News

    Trials
    25d
    ELSPIRE: A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (clinicaltrials.gov)
    P3, N=72, Not yet recruiting, Ipsen
    New P3 trial
    |
    elafibranor (GFT505)
    3ms
    ELMWOOD: A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. (clinicaltrials.gov)
    P2, N=60, Recruiting, Ipsen | Trial completion date: Dec 2025 --> Dec 2024
    Trial completion date
    |
    elafibranor (GFT505)
    7ms
    ELMWOOD: A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. (clinicaltrials.gov)
    P2, N=60, Recruiting, Ipsen | Trial primary completion date: Feb 2024 --> Dec 2024
    Trial primary completion date
    |
    elafibranor (GFT505)
    7ms
    ELATIVE: Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) (clinicaltrials.gov)
    P3, N=161, Active, not recruiting, Ipsen | Trial primary completion date: Sep 2023 --> Jun 2023
    Trial primary completion date
    |
    elafibranor (GFT505)
    11ms
    Design, synthesis and anti-NASH effect evaluation of novel GFT505 derivatives in vitro and in vivo. (PubMed, Eur J Med Chem)
    Methionine-choline deficiency (MCD) induced C57BL/6J NASH model mice was used for the in vivo biological experiments and the compound 3d demostrated lower liver toxicity than that of GFT 505 in the body at the same dose, and it did more effectively improve hyperlipidemia, liver fat degeneration and liver inflammation as well as significantly enhance the content of the GSH which is inportant for the liver protection. This study suggested that the compound 3d is a very promising lead compound for the treatment of NASH.
    Preclinical • Journal
    |
    elafibranor (GFT505)
    4years
    Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH. (PubMed, Pharmacol Res)
    This reduction in inflammatory response was NFκB-mediated. In summary, this human-relevant, in vitro system proved to be a sensitive testing tool for the investigation of novel anti-NASH compounds.
    Journal
    |
    IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCL5 (Chemokine (C-C motif) ligand 5) • CASP3 (Caspase 3) • CCL2 (Chemokine (C-C motif) ligand 2) • IL1A (Interleukin 1, alpha) • CCL7 (Chemokine (C-C motif) ligand 7)
    |
    elafibranor (GFT505)
    over5years
    Elafibranor Administration Prevents Liver Tumor Development in Mouse Models of Nash (AASLD 2018)
    Preneoplastic lesion development was prevented to a significant extent upon ELA treatment. In addition, ELA directly reduces tumour cell proliferation. These results open new perspectives to evaluate ELA for liver cancer prevention and treatment in NAFLD patients.References:.
    Preclinical
    |
    AFP (Alpha-fetoprotein) • GPC3 (Glypican 3)
    |
    elafibranor (GFT505)